CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 72 enrolled
Drug / intervention
Metoprolol Tartrate +1 moredrug
Likely dose
Metoprolol Tartrate 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03138603
NCT03138603Phase 3Completed
CompareCT.gov

Metoprolol to Reduce Perioperative Myocardial Injury

University of Chicago·interventional·Posted May 3, 2017·Updated Jan 28, 2026

In Brief

A Phase 3 clinical trial evaluating Metoprolol Tartrate and Placebo for Heart Diseases. Completed, enrolled 72 participants across 2 sites.

Detailed Summary

The purpose of this research study is to test if a commonly used, FDA-approved medication, called metoprolol, given at the conclusion of anesthesia following surgery, and during postoperative admission, reduces the possibility of heart related complications in patients with coronary artery disease (CAD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Diseases
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Washington University School of Medicine

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 3, 2017
Enrollment StartDec 1, 2016
Primary CompletionApr 18, 2023
Study CompletionAug 29, 2023
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 9.2 years ago

Interventions

Metoprolol Tartratedrug

Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).

Placebodrug

Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).